Investors & Media

Press Release

BioCryst to Present at Upcoming Investor Conferences

November 12, 2021 at 7:02 AM EST

RESEARCH TRIANGLE PARK, N.C., Nov. 12, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the following upcoming virtual investor conferences:

  • 2021 Jefferies London Healthcare Conference—pre-recorded fireside chat available beginning Thursday, November 18 at 3:00 a.m. ET

  • Piper Sandler 33rd Annual Virtual Healthcare Conference—pre-recorded fireside chat available beginning Monday, November 22 at 10 a.m. ET

  • 4th Annual Evercore ISI HeathCONx Conference on Wednesday, December 1 at 3:05 p.m. ET

  • JMP Securities Hematology and Oncology Summit on Monday, December 6 at 1:00 p.m. ET

Links to the live audio webcast of the Evercore and JMP presentations, and replays of all presentations, may be accessed in the Investors section of BioCryst’s website at

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States, the European Union, Japan, the United Arab Emirates and the United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection) has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at


John Bluth
+1 919 859 7910

Catherine Collier Kyroulis
+1 917 886 5586